| Autor: |
Qiu, L., Zhou, K., Wang, T., Pan, L., Xu, W., Jin, J., Zhang, W., Hu, Y., Hu, J., Feng, R., Li, P., Liu, Z., Liu, P., Jing, H., Gao, S., Yu, K., Wang, Z., Zhang, H., Zhu, X., Sun, Z. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p740-742, 3p |
| Abstrakt: |
B Introduction: b Zanubrutinib is an irreversible, potent, next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target inhibition. A favorable safety profile was also observed in pts from China with zanubrutinib compared with ibrutinib, with lower rates of treatment discontinuations and serious AEs in patients with R/R CLL/SLL. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text